---
title: "Xolair (omalizumab) in allergic asthma: Clinical trials questions"
description: "Clinical trials questions on Xolair (omalizumab) in allergic asthma, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Study results and Pediatric efficacy. Questions: How were the Xolair allergic asthma trials designed (Studies 1 and 2)? How much did Xolair reduce asthma exacerbations vs placebo (Trials 1 and 2)? Does Xolair improve asthma symptoms and FEV1 vs placebo (Trial 1)? Does Xolair reduce asthma hospitalizations? 4 further questions follow. 8 questions quoted from 2 sources."
canonical: "https://www.evicenter.com/medical-information/xolair--allergic-asthma/clinical-trials"
published: "2026-11-14T00:11:41-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Xolair (omalizumab) in allergic asthma: Clinical trials questions

Manufacturer: Genentech, Inc.; Novartis Pharmaceuticals Corporation  
Prescribing information: [Xolair](https://www.gene.com/download/pdf/xolair_prescribing.pdf)

Questions that apply to every indication of Xolair are on [Xolair (omalizumab), all indications](https://www.evicenter.com/medical-information/xolair).

## Clinical trials

<a id="xolair-trial-design"></a>

### How were the Xolair allergic asthma trials designed (Studies 1 and 2)?

> “Identical, 28-week, randomized, double-blind, placebo-controlled studies evaluating the number of exacerbations in a total of 1071 patients aged 12 to 76 years with moderate to severe persistent allergic asthma who were symptomatic despite ICS treatment<sup>4,10,11</sup>”

Source: [XOLAIR: XOLAIR® (omalizumab) Clinical Trials | Study Design | HCP, captured 2026-11-13](https://www.xolairhcp.com/allergic-asthma/efficacy/clinical-trial-information.html#:~:text=Identical%2C%2028%2Dweek%2C%20randomized%2C%20double%2Dblind%2C%20placebo%2Dcontrolled,who%20were%20symptomatic%20despite%20ICS)

> “Patients received XOLAIR or placebo every 2 or 4 weeks for 16 weeks with an unchanged BDP dose unless an acute exacerbation necessitated an increase. Patients then entered a 12-week ICS-reduction phase during which ICS dose reduction was attempted in a stepwise manner<sup>4,10,11</sup>”

Source: [XOLAIR: XOLAIR® (omalizumab) Clinical Trials | Study Design | HCP, captured 2026-11-13](https://www.xolairhcp.com/allergic-asthma/efficacy/clinical-trial-information.html#:~:text=Patients%20received%20XOLAIR%20or%20placebo,was%20attempted%20in%20a%20stepwise)

> “Primary endpoint: Number of exacerbations<sup>10,11</sup>”

Source: [XOLAIR: XOLAIR® (omalizumab) Clinical Trials | Study Design | HCP, captured 2026-11-13](https://www.xolairhcp.com/allergic-asthma/efficacy/clinical-trial-information.html#:~:text=Primary%20endpoint%3A%20Number%20of)

> “Exacerbation was defined as: A worsening of asthma that required treatment with systemic corticosteroidsor a doubling of the patient’s baseline ICS dose<sup>4</sup>”

Source: [XOLAIR: XOLAIR® (omalizumab) Clinical Trials | Study Design | HCP, captured 2026-11-13](https://www.xolairhcp.com/allergic-asthma/efficacy/clinical-trial-information.html#:~:text=Exacerbation%20was%20defined%20as%3A%20A,of%20the%20patient%E2%80%99s%20baseline%20ICS)

## Study results

<a id="xolair-exacerbation-reduction"></a>

### How much did Xolair reduce asthma exacerbations vs placebo (Trials 1 and 2)?

> “Identical, 28-week, randomized, double-blind, placebo-controlled studies evaluating the number of exacerbations in a total of 1071 patients aged 12 to 76 years with moderate to severe persistent allergic asthma who were symptomatic despite ICS treatment<sup>4,10,11</sup>”

Source: [XOLAIR: XOLAIR® (omalizumab) Clinical Trials | Study Design | HCP, captured 2026-11-13](https://www.xolairhcp.com/allergic-asthma/efficacy/clinical-trial-information.html#:~:text=Identical%2C%2028%2Dweek%2C%20randomized%2C%20double%2Dblind%2C%20placebo%2Dcontrolled,who%20were%20symptomatic%20despite%20ICS)

> “In both Asthma Trials 1 and 2 the number of exacerbations per patient was reduced in 
> patients treated with XOLAIR compared with placebo (Table 11).”

Source: [XOLAIR: Prescribing information, page 31, captured 2026-11-13](https://www.gene.com/download/pdf/xolair_prescribing.pdf#page=31)

> “Table 11. Frequency of Asthma Exacerbations per Patient by Phase in Asthma 
> Trials 1 and 2 
>
> Stable Steroid Phase (16 wks) 
>
> Asthma Trial 1 
> Asthma Trial 2 
> Exacerbations per 
> patient 
> XOLAIR 
> N=268  
> Placebo 
> N=257  
> XOLAIR 
> N=274  
> Placebo 
> N=272  
> 0 
> 85.8% 
> 76.7% 
> 87.6% 
> 69.9% 
> 1 
> 11.9% 
> 16.7% 
> 11.3% 
> 25.0% 
> ≥2 
> 2.2% 
> 6.6% 
> 1.1% 
> 5.1% 
> p-Value 
> 0.005 
> <0.001 
> Mean number 
> exacerbations/patient 
> 0.2 
> 0.3 
> 0.1 
> 0.4 
>
> Steroid Reduction Phase (12 wks) 
> Exacerbations per 
> patient 
> XOLAIR 
> N=268  
> Placebo 
> N=257  
> XOLAIR 
> N=274 
> Placebo 
> N=272  
> 0 
> 78.7% 
> 67.7% 
> 83.9% 
> 70.2% 
> 1 
> 19.0% 
> 28.4% 
> 14.2% 
> 26.1% 
> ≥2 
> 2.2% 
> 3.9% 
> 1.8% 
> 3.7% 
> p-Value 
> 0.004 
> <0.001 
> Mean number 
> exacerbations/patient 
> 0.2 
> 0.4 
> 0.2 
> 0.3”

Source: [XOLAIR: Prescribing information, page 32, captured 2026-11-13](https://www.gene.com/download/pdf/xolair_prescribing.pdf#page=32)

Note: The table text lists each row's values in the header order: Asthma Trial 1 XOLAIR (N=268), Asthma Trial 1 placebo (N=257), Asthma Trial 2 XOLAIR (N=274), Asthma Trial 2 placebo (N=272). The stable steroid phase lasted 16 weeks and the steroid reduction phase 12 weeks.

<a id="xolair-symptoms-fev1"></a>

### Does Xolair improve asthma symptoms and FEV1 vs placebo (Trial 1)?

> “Identical, 28-week, randomized, double-blind, placebo-controlled studies evaluating the number of exacerbations in a total of 1071 patients aged 12 to 76 years with moderate to severe persistent allergic asthma who were symptomatic despite ICS treatment<sup>4,10,11</sup>”

Source: [XOLAIR: XOLAIR® (omalizumab) Clinical Trials | Study Design | HCP, captured 2026-11-13](https://www.xolairhcp.com/allergic-asthma/efficacy/clinical-trial-information.html#:~:text=Identical%2C%2028%2Dweek%2C%20randomized%2C%20double%2Dblind%2C%20placebo%2Dcontrolled,who%20were%20symptomatic%20despite%20ICS)

> “Measures of airflow (FEV1) and asthma symptoms were also evaluated in these trials.  The 
> clinical relevance of the treatment-associated differences is unknown.  Results from the 
> stable steroid phase Asthma Trial 1 are shown in Table 12.  Results from the stable steroid 
> phase of Asthma Trial 2 and the steroid reduction phases of both Asthma Trials 1 and 2 were 
> similar to those presented in Table 12.”

Source: [XOLAIR: Prescribing information, page 31, captured 2026-11-13](https://www.gene.com/download/pdf/xolair_prescribing.pdf#page=31)

> “Table 12. Asthma Symptoms and Pulmonary Function During  
> Stable Steroid Phase of Asthma Trial 1 
>
> XOLAIR 
> N=268<sup>*</sup> 
> Placebo 
> N=257<sup>*</sup> 
> Endpoint 
> Mean 
> Baseline 
> Median Change 
> (Baseline to Wk 16) 
> Mean 
> Baseline 
> Median Change 
> (Baseline to Wk 16) 
> Total asthma symptom score 
> 4.3 
> –1.5<sup>†</sup> 
> 4.2 
> –1.1<sup>†</sup> 
> Nocturnal asthma score 
> 1.2 
> –0.4<sup>†</sup> 
> 1.1 
> –0.2<sup>†</sup> 
> Daytime asthma score 
> 2.3 
> –0.9<sup>†</sup> 
> 2.3 
> –0.6<sup>†</sup> 
> FEV1 % predicted 
> 68 
> 3<sup>†</sup> 
> 68 
> 0<sup>†</sup> 
> Asthma symptom scale: total score from 0 (least) to 9 (most); nocturnal and daytime scores from 0 (least) to 4 
> (most symptoms). 
> <sup>*</sup>  Number of patients available for analysis ranges 255-258 in the XOLAIR group and 238-239 in the placebo 
> group. 
> <sup>†</sup> Comparison of XOLAIR versus placebo (p < 0.05).”

Source: [XOLAIR: Prescribing information, page 32, captured 2026-11-13](https://www.gene.com/download/pdf/xolair_prescribing.pdf#page=32)

Note: Table 12 lists, for each endpoint, the XOLAIR mean baseline and median change to Week 16, then the placebo mean baseline and median change.

<a id="xolair-hospitalizations"></a>

### Does Xolair reduce asthma hospitalizations?

> “In all three trials an exacerbation was defined as a worsening of asthma that required 
> treatment with systemic corticosteroids or a doubling of the baseline ICS dose.  Most 
> exacerbations were managed in the outpatient setting and the majority were treated with 
> systemic steroids.  Hospitalization rates were not significantly different between XOLAIR 
> and placebo-treated patients; however, the overall hospitalization rate was small.  Among 
> those patients who experienced an exacerbation, the distribution of exacerbation severity was 
> similar between treatment groups.”

Source: [XOLAIR: Prescribing information, page 31, captured 2026-11-13](https://www.gene.com/download/pdf/xolair_prescribing.pdf#page=31)

<a id="xolair-trial-3-severe-asthma"></a>

### Did Xolair reduce exacerbations in severe asthma on high-dose steroids (Trial 3)?

> “A 32-week, randomized, double-blind, placebo-controlled study designed to evaluate ICS reduction in 341 patients aged 12 to 76 years with severe allergic asthma. Exacerbation reduction was also evaluated as a secondary endpoint; however, this study was not powered to show statistical differences in exacerbation reduction<sup>4,8</sup>”

Source: [XOLAIR: XOLAIR® (omalizumab) Clinical Trials | Study Design | HCP, captured 2026-11-13](https://www.xolairhcp.com/allergic-asthma/efficacy/clinical-trial-information.html#:~:text=A%2032%2Dweek%2C%20randomized%2C%20double%2Dblind%2C%20placebo%2Dcontrolled,show%20statistical%20differences%20in%20exacerbation)

> “Unlike in Studies 1 and 2, there was no restriction on screening FEV1, and LABAs were allowed. Patients were receiving ≥1000 μg/d ICS (fluticasone), and a subset was also receiving OCS.”

Source: [XOLAIR: XOLAIR® (omalizumab) Clinical Trials | Study Design | HCP, captured 2026-11-13](https://www.xolairhcp.com/allergic-asthma/efficacy/clinical-trial-information.html#:~:text=Unlike%20in%20Studies%201%20and,subset%20was%20also%20receiving%20OCS.)

> “The number of exacerbations in patients treated with XOLAIR was similar to that in placebo-
> treated patients (Table 13).  The absence of an observed treatment effect may be related to 
> differences in the patient population compared with Asthma Trials 1 and 2, study sample 
> size, or other factors.  
> Table 13. Percentage of Patients with Asthma Exacerbations by Subgroup and  
> Phase in Asthma Trial 3 
>
> Stable Steroid Phase (16 wks) 
>
> Inhaled Only 
> Oral + Inhaled 
>
> XOLAIR 
> N=126 
> Placebo 
> N=120 
> XOLAIR 
> N=50 
> Placebo 
> N=45 
> % Patients with ≥1 
> exacerbations 
> 15.9% 
> 15.0% 
> 32.0% 
> 22.2% 
> Difference 
> (95% CI) 
> 0.9 
> (–9.7, 13.7) 
> 9.8 
> (–10.5, 31.4) 
>
> Steroid Reduction Phase (16 wks) 
>
> XOLAIR 
> N=126 
> Placebo 
> N=120 
> XOLAIR 
> N=50 
> Placebo 
> N=45 
> % Patients with ≥1 
> exacerbations 
> 22.2% 
> 26.7% 
> 42.0% 
> 42.2% 
> Difference 
> (95% CI) 
> –4.4 
> (–17.6, 7.4) 
> –0.2 
> (–22.4, 20.1)”

Source: [XOLAIR: Prescribing information, page 33, captured 2026-11-13](https://www.gene.com/download/pdf/xolair_prescribing.pdf#page=33)

Note: Table 13 lists each row's values in the header order: inhaled corticosteroids only, XOLAIR (N=126) and placebo (N=120); oral plus inhaled corticosteroids, XOLAIR (N=50) and placebo (N=45). Both phases lasted 16 weeks.

<a id="xolair-who-did-not-benefit"></a>

### Which asthma patients did not have fewer exacerbations on Xolair?

> “In all three of the trials, a reduction of asthma exacerbations was not observed in the 
> XOLAIR-treated patients who had FEV1>80% at the time of randomization.  Reductions in 
> exacerbations were not seen in patients who required oral steroids as maintenance therapy.”

Source: [XOLAIR: Prescribing information, page 33, captured 2026-11-13](https://www.gene.com/download/pdf/xolair_prescribing.pdf#page=33)

## Pediatric efficacy

<a id="xolair-pediatric-trial-4"></a>

### How much did Xolair reduce exacerbations in children 6 to 11 (Trial 4)?

> “Asthma Trial 4 was a 52-week study that evaluated the safety and efficacy of XOLAIR as 
> add-on therapy in 628 pediatric patients ages 6 to <12 years with moderate to severe asthma 
> inadequately controlled despite the use of inhaled corticosteroids (fluticasone propionate DPI 
> ≥200 mcg/day or equivalent) with or without other controller asthma medications.  Eligible 
> patients were those with a diagnosis of asthma >1 year, a positive skin prick test to at least 
> one perennial aeroallergen, and a history of clinical features such as daytime and/or night-
> time symptoms and exacerbations within the year prior to study entry.  During the first 24 
> weeks of treatment, steroid doses remained constant from baseline.  This was followed by a 
> 28-week period during which inhaled corticosteroid adjustment was allowed.”

Source: [XOLAIR: Prescribing information, page 34, captured 2026-11-13](https://www.gene.com/download/pdf/xolair_prescribing.pdf#page=34)

> “The primary efficacy variable was the rate of asthma exacerbations during the 24-week, fixed 
> steroid treatment phase.  An asthma exacerbation was defined as a worsening of asthma 
> symptoms as judged clinically by the investigator, requiring doubling of the baseline inhaled 
> corticosteroid dose for at least 3 days and/or treatment with rescue systemic (oral or IV) 
> corticosteroids for at least 3 days.  At 24 weeks, the XOLAIR group had a statistically 
> significantly lower rate of asthma exacerbations (0.45 vs. 0.64) with an estimated rate ratio of 
> 0.69 (95% CI: 0.53, 0.90).   
> The XOLAIR group also had a lower rate of asthma exacerbations compared to placebo over 
> the full 52-week double-blind treatment period (0.78 vs. 1.36; rate ratio: 0.57; 95% CI: 0.45, 
> 0.72).  Other efficacy variables such as nocturnal symptom scores, beta-agonist use, and 
> measures of airflow (FEV1) were not significantly different in XOLAIR-treated patients 
> compared to placebo.”

Source: [XOLAIR: Prescribing information, page 34, captured 2026-11-13](https://www.gene.com/download/pdf/xolair_prescribing.pdf#page=34)

<a id="xolair-pediatric-trial-5"></a>

### Did Xolair reduce exacerbations in children with well-controlled asthma (Trial 5)?

> “Asthma Trial 5 was a 28-week randomized, double blind, placebo-controlled study that 
> primarily evaluated safety in 334 pediatric patients, 298 of whom were 6 to <12 years of age, 
> with moderate to severe asthma who were well-controlled with inhaled corticosteroids 
> (beclomethasone dipropionate 168-420 mcg/day).  A 16-week steroid treatment period was 
> followed by a 12-week steroid dose reduction period.  Patients treated with XOLAIR had 
> fewer asthma exacerbations compared to placebo during both the 16-week fixed steroid 
> treatment period (0.18 vs. 0.32; rate ratio: 0.58; 95% CI: 0.35, 0.96) and the 28-week 
> treatment period (0.38 vs. 0.76; rate ratio: 0.50; 95% CI: 0.36, 0.71).”

Source: [XOLAIR: Prescribing information, page 34, captured 2026-11-13](https://www.gene.com/download/pdf/xolair_prescribing.pdf#page=34)

Note: The label describes Asthma Trial 5 as a study that primarily evaluated safety.

## Related pages
- [Medical information: Xolair (omalizumab): Allergic asthma](https://www.evicenter.com/medical-information/xolair--allergic-asthma)
- [Indication](https://www.evicenter.com/medical-information/xolair--allergic-asthma/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/xolair--allergic-asthma/pharmacology)
- [Safety](https://www.evicenter.com/medical-information/xolair--allergic-asthma/safety)
- [Specific populations](https://www.evicenter.com/medical-information/xolair--allergic-asthma/specific-populations)
- [Drug interactions](https://www.evicenter.com/medical-information/xolair--allergic-asthma/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/xolair--allergic-asthma/dosing-and-administration)
- [Access and coverage](https://www.evicenter.com/medical-information/xolair--allergic-asthma/access-and-coverage)
